Policy adjustments make India a worldwide Pharma powerhouse, says Hikal Vice Chairman and Managing Director Hiremath

“With the implementation of latest coverage frameworks, India’s pharmaceutical contract manufacturing business is rising as a key participant on the worldwide stage,” mentioned Sameer Hiremath, Vice Chairman and Managing Director, Hikal Ltd.

Hikal Ltd. caters to prescription drugs, life sciences, biotechnology, agrochemicals, and specialty chemical substances corporations to ship lively components, intermediates and R&D providers.

He mentioned for a few years, Indian drug producers have been seen because the inexpensive backups—able to step in when world provide chains faltered, however not often trusted with high-stakes manufacturing. That narrative is now present process a speedy transformation.

Multiple worldwide initiatives—such because the U.S.’s BIOSECURE Act, Europe’s transfer towards strategic autonomy, and Japan’s re-evaluation of provide chain dependencies—have aligned with India’s personal pharmaceutical reforms, he mentioned in a be aware.

Together, they’ve propelled India from a secondary choice to a central determine in pharma provide chains, he added.

Mr. Hiremath mentioned India’s ₹15,000-crore PLI scheme for bulk medication and a broader PLI for formulations have improved the financial attractiveness of Indian manufacturing. “The authorities’s assist has aligned home circumstances with world enterprise expectations, from APIs to biologics,” he mentioned.

“Together, these developments have unlocked huge potential. Grand View Research, initiatives India’s CDMO market to develop to $21 billion by 2030—an 8% CAGR. Consulting corporations like McKinsey imagine that these strategic shifts might push India’s pharma exports past $60 billion within the coming years from $28 billion presently,” he mentioned.

Stating that also challenges stay, he mentioned the route is evident. “India nonetheless depends closely on China for key inputs like fermentation-grade intermediates. Additionally, the BIOSECURE Act might drive up U.S. manufacturing prices, triggering resistance over pricing,” Mr. Hiremath mentioned.

“Yet the bigger pattern is simple: Indian CDMOs at the moment are entrance and centre. Innovators not name on them simply in emergencies—they’re co-creating from the beginning,” he added.